Navigation Links
Faruqi & Faruqi, LLP Announces Investigation of ViroPharma Incorporated
Date:5/29/2012

NEW YORK, May 29, 2012 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential securities fraud at ViroPharma Incorporated ("ViroPharma" or the "Company") (NASDAQ: VPHM).

(Logo: http://photos.prnewswire.com/prnh/20120119/MM38856LOGO )

The investigation focuses on the Company's product Vancocin, which uses the Vancomycin antibiotic.  On December 14, 2011, the Company issued a press release stating that it believed that Vancocin would have three years of marketing exclusivity due to changes in its label, and that generic Vancomycin capsules would not be approved during that period.  Following this news, ViroPharma's stock price rose 17.9% to close at $27.80 per share on December 14, 2011.

However, on April 10, 2012, ViroPharma announced that the FDA had informed the Company that Vancocin's new label would not qualify the product for three additional years of exclusivity, and that the FDA had indicated it is approving three applications for generic Vancomycin capsules.  Following this news, the price of ViroPharma common stock dropped 22% to close at $22.44 per share on April 10, 2012. 

Request more information now by clicking here:  www.faruqilaw.com/VPHM

Take Action
If you purchased ViroPharma securities between December 14, 2011 and April 9, 2012 and would like to discuss your legal rights, visit www.faruqilaw.com/VPHM. You can also contact us by calling Richard Gonnello or Francis McConville toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to rgonnello@faruqilaw.com or fmcconville@faruqilaw.com.  Faruqi & Faruqi, LLP also encourages anyone with information regarding ViroPharma's conduct to contact the firm, including whistleblowers, former employees, shareholders and others.


Attorney Advertising.  The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com).  Prior results do not guarantee or predict a similar outcome with respect to any future matter.  We welcome the opportunity to discuss your particular case.  All communications will be treated in a confidential matter.

FARUQI & FARUQI, LLP
369 Lexington Avenue, 10th Floor
New York, NY 10017
Attn:  Richard Gonnello, Esq.
rgonnello@faruqilaw.com
Francis McConville, Esq.
fmcconville@faruqilaw.com
Telephone: (877) 247-4292 or (212) 983-9330

 


'/>"/>
SOURCE Faruqi & Faruqi, LLP
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Substantial Losses Investing in Chelsea Therapeutics International, Ltd. to Contact the Firm
2. Faruqi & Faruqi, LLP Announces Investigation of ZELTIQ Aesthetics, Inc.
3. Faruqi & Faruqi, LLP Announces Investigation of BioSante Pharmaceuticals, Inc.
4. Faruqi & Faruqi, LLP Announces Investigation of GenVec, Inc.
5. Masimo to Present at William Blair & Company 32nd Annual Growth Stock Conference
6. Acacia Pharma Announces Excellent Phase II Results for APD421 in Post-Operative Nausea & Vomiting (PONV)
7. MicroRNA Research to Trigger Tremendous Growth in Related Tools Market, Says Frost & Sullivan
8. Frost & Sullivan Recognizes Labcyte for its Commitment to Innovation and Addressing Unmet Needs in the Liquid Handling Market
9. Oramed Pharmaceuticals to Present at the 11th National Life Science & Technology Week ILSI-BIOMED Conference; Tel Aviv, Israel, 2012
10. Medical Device Developers - Network at MD&M East Next Week
11. Heightened Awareness, Coupled with Expanding Patient Pool, Stimulates Sleep Apnea Diagnostics and Sleep Services Market, Says Frost & Sullivan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2017)... Feb. 27, 2017  A landmark study ... , MBBS, PhD, FRACS, of  Sydney Heart and ... Sydney will be published in the February 28, ... American College of Cardiology . According to the study, which ... bypass surgery technique (anOPCABG) reduced postoperative stroke ...
(Date:2/27/2017)...  International Biophysics Corporation, a global medical device manufacturer based ... 34% revenue growth in 2016 when compared to the previous ... growth was fueled by its AffloVest® sales in ... of its global sales of surgical product lines. ... enter our 25 th year in delivering high-quality, innovative ...
(Date:2/27/2017)... Md. , Feb. 27, 2017  RegeneRx ... a clinical-stage drug development company focused on tissue ... licensee for RGN-137, GtreeBNT Co., Ltd., received a ... Phase 3 clinical trial design for RGN-137 to ... wound healing gel that incorporates Thymosin beta 4 ...
Breaking Medicine Technology:
(Date:2/27/2017)... Sedona, Arizona (PRWEB) , ... February 27, 2017 ... ... Premier Center for Shamanic Healing and Spiritual Awakening, is happy to announce ... reboot for mind and body, these individual customized retreats offer the winter-weary soul ...
(Date:2/27/2017)... ... 27, 2017 , ... This webinar , sponsored by ... tool to characterize particle size distributions in the field of geoscience and soil ... scientific findings. It describes methods of optimized and standardized sample collection, preparation and ...
(Date:2/27/2017)... ... 27, 2017 , ... Silicon Valley Hair Institute, a professional ... informational post on robotic hair transplantation. San Francisco residents may be confused over ... Unit Transplantation (FUT) can sound similar. Either treatment can be used to provide ...
(Date:2/26/2017)... ... February 26, 2017 , ... This is an ... world’s first to be ISO/IEC 17025:2005 INAB accredited for Der p 1 (house ... is the globally recognised standard that sets out requirements for the technical competence ...
(Date:2/26/2017)... ... February 26, 2017 , ... ODH, Inc.™ announced today it will ... the Sheraton Pentagon City Hotel in Arlington, VA. ODH’s director of medical strategy, Candace ... analytics to improve Medicaid population health management. , ODH will also have an exhibit ...
Breaking Medicine News(10 mins):